Advances in the therapeutic management of Pancreatic Cancer - Current and future perspectives
Joint Event on 17th International Conference on Nutrition and Fitness & 2nd International Conference on Gastroenterology and Digestive Disorders
May 23-24, 2019 | Vienna, Austria
Scheithauer W
Medical University Vienna, Austria
Keynote : J Nutr Hum Health
Abstract:
The overall 5-year survival rate for pancreatic cancer (8%) has changed little over the past few decades, and this tumour is predicted to be the second leading cause of cancer-related mortality in the next decade in Western countries. During the past few years, however, clinically relevant improvements in first-line and secondline palliative therapies and significant progress in increasing survival with adjuvant treatment have been achived. The potential of neoadjuvant therapies also offers opportunities to improve outcomes. This review will bring together information on achievements to date, and where successes are likely to be achieved in the future. The questions of how we should approach the development of pancreatic cancer treatments, including those for patients with metastatic, locally advanced and borderline resectable pancreatic cancer, as well as for patients with resected tumours will be addressed.
Biography:
Scheithauer W is a Professor of Internal Medicine at the Medical University in Vienna, Austria. His main research interests include the preclinical and clinical evaluation of new anticancer agents and biologics, especially in gastrointestinal malignancies, on which he has published 273 original papers in peer-reviewed journals, more than 60 book chapters, and over 600 abstracts.
E-mail: werner.scheithauer@meduniwien.ac.at
PDF HTML